Background: Many patients undergoing ventricular tachycardia (VT) or premature ventricular complex (PVC) ablation receive antithrombotic medications. Their uninterrupted use has the potential to affect complication rates.
INTRODUCTION
An increasing number of patients receiving anticoagulants and antiplatelet agents require ventricular tachycardia (VT) or premature ventricular complex (PVC) ablation. The risks of interrupting anticoagulation must be balanced against potential bleeding risks associated with continuation.
Until recently, patients receiving anticoagulant therapy with either a vitamin K antagonist (VKA), for example, warfarin, or a non-vitamin K anticoagulant (NOAC), would typically stop these prior to VT or PVC ablation in an attempt to minimize risks of bleeding. The change in practice in relation to anticoagulation for patients undergoing atrial fibrillation (AF) ablation, whereby these agents are continued uninterrupted through the procedure, [1] [2] [3] [4] has been accompanied by similar changes in the setting of VT and PVC ablation, with increasing numbers of these procedures now also being performed with uninterrupted anticoagulant therapy. In addition, approximately half of VT ablations are performed on patients with ischemic heart disease (IHD), many of whom are receiving single or dual antiplatelet therapy.
Adequate antithrombotic therapy during the procedure is important to minimize the risks of both overt and subclinical thromboemboli. 5 The most recent European Heart Rhythm Association position document on antithrombotic management for electrophysiology procedures suggests continuing VKAs uninterrupted for endocardial left ventricular (LV) ablations, but discontinuing 3-5 days prior to anticipated epicardial access, with bridging therapeutic doses of heparin. It advises discontinuation of NOAC therapy ≥24 h prior to LV ablation. 6 However, there is no advice on the safety of continuing dual antiplatelet therapy.
To investigate the safety of performing VT or PVC ablation without interruption of anticoagulant and/or antiplatelet therapy, we assessed the incidence of complications in a contemporaneous cohort of patients undergoing these procedures. and/or prophylactic LMWH on the day of procedure); and group (C) no antithrombotics group (patients not receiving any antithrombotic agents). The INR on the day of procedure was ascertained by either laboratory result or documented point-of-care testing. NOAC use on the day of procedure was confirmed either by review of the prescription chart or documentation in the patient's notes or procedure report.
METHODS

This
Antiplatelet use was determined by review of prescription charts and medical records.
Periprocedural major complications in each group were defined as those resulting from the procedure and occurring prior to discharge from hospital, together with one or more of: (a) causing longterm harm, (b) delaying discharge, and (c) requiring procedural/surgical intervention. These were assessed by review of patients' medical records and procedure reports. Patient information was anonymized.
Antithrombotic therapy
For patients receiving antiplatelet agents (aspirin or clopidogrel), these were continued uninterrupted through the procedure. Warfarin or NOAC therapy was given prior to and following the procedure according to a number of factors, including indication for anticoagulant, procedural urgency, INR stability, and cardiologist preference. Epicardial access was obtained via the subxiphoid approach, in the manner described by Sosa et al. 7 This was obtained following endocardial LV mapping, and therefore after heparinization, and in the presence of ACT > 250 s, based on previous work within the unit demonstrating safety of this approach. 8 Coronary angiography was performed in those patients in whom epicardial ablation was planned in the basal to midventricular regions, to avoid inadvertent radiofrequency energy damage to epicardial vessels. Proximity of the phrenic nerve was excluded via pacing prior to epicardial ablation of the lateral LV.
Catheter ablation procedure
Following LV endocardial ablation, if the patient was not already receiving an antiplatelet or anticoagulant agent, aspirin 300 mg daily was commenced and continued for at least 6 weeks.
Statistics
Univariable and multivariable analyses were performed with binary logistic regression using Stata/IC 14.2 (StataCorp, College Station, TX, USA). Predictors with P < 0.1 in univariable analysis were entered into the multivariable model, as well as antithrombotic groups, given the focus of the study and mechanistic plausibility. Between-group comparison of procedural complication rates was also assessed with Fisher's exact test. A P value ˂ 0.05 was considered significant.
RESULTS
Patient characteristics and comorbidities
Demographic and comorbidity data for each group are shown in Table 1 . There were significant differences between groups for all variables, except prevalence of hypertension. Of particular note were the eGFR = estimated glomerular filtration rate; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction. younger average age of Group C, the male preponderance of Groups A and B, the higher prevalence of IHD in Group B, and the lower average LV ejection fraction in Groups A and B. These differences to some extent reflect the proportions of patients in each group undergoing VT or PVC ablation (discussed below). Table 2 shows the use of antithrombotic agents for patients in Groups A and B. For patients in Group A receiving warfarin, the mean INR on the day of procedure was 2.5 (1.6-4.3). The INR was 1.5-1.9 in seven patients, 2.0-3.5 in 38 patients, and ˃3.5 in only two patients.
TA B L E 2 Antithrombotic use in Groups A and B
Groups
Antithrombotic drug Number
Antithrombotic use
Procedural data
The largest number of procedures were performed for patients in Group C, and interestingly there was a fairly even split in the proportion of VT versus PVC ablations in this group despite the lower prevalence of IHD. Group A had the largest proportion of VT ablations (Table 3 ).
As expected, most patients in each group had femoral venous access. The proportion of femoral artery and trans-septal access were lower in Group C than Groups A and B, likely reflecting the greater were on warfarin (mean INR 2.5), and two of 18 received a NOAC on the day of the procedure.
The proportion of procedures in each group in which LV ablation was performed was as follows: Group A, 81%; Group B, 79%; and Group C, 48%.
Complications
There were 47 patients in Group A, with four suffering complications, giving a procedural complication rate of 8.5% (Figure 1 There were 108 patients in Group C. Six suffered complications, giving rise to a procedural complication rate of 5.6%.
A 49-year-old male undergoing VT ablation with an epicardial approach suffered cardiac tamponade that was drained percutaneously. He also developed a hematoma lateral to the stomach, with moderate hemoperitoneum.
A 93-year-old male undergoing VT ablation suffered cardiac tamponade requiring drainage, as well as a left groin hematoma related to femoral artery access.
A 79-year-old male suffered cardiac tamponade during VT ablation, and was transferred to the intensive treatment unit, where he died the following day.
A 39-year-old male undergoing VT ablation suffered a probable gastric puncture during attempted epicardial access. The patient remained nil by mouth for 3 days and there were no sequelae.
A 32-year-old male undergoing VT ablation suffered a groin hematoma that was managed conservatively but which delayed discharge.
And finally, a 58-year-old male undergoing VT ablation via epi- In summary, with regard to complications attributable to bleeding, the incidence of vascular access-related hematoma in Groups A, B, and C was 2.1%, 0%, and 1.9%, respectively. And while there were no pericardial effusions, tamponades, or abdominal visceral injuries in Group A, the respective rates in Group B, were 2.2%, 4.3%, and 0%, and in Group C, 0.9%, 2.8%, and 1.9% (Figure 1 ).
Survival to discharge
Overall, 97% of patients survived to hospital discharge. Of the seven patients who did not survive, two were in Group A, one was in Group B, and four were in Group C. There was one procedure-related death (see above).
Predictors of complications
In univariable analysis using logistic regression, only age was significant with = 0.1 (Table 4 ). In multivariable logistic regression analysis, age and group were included, given the latter's clinical significance and relevance to the study. Age reached near significance (odds ratio
[OR], 1.04, 95% confidence interval, 1.00-1.09; P, 0.054). Comparing complication rates between groups, with Group C as the reference group, there were no significant differences (A vs C, P = 0.822; B vs C, P = 0.573). Between-group comparison of complication rates with
Fisher's Exact test also found no significant difference (P = 0.804).
DISCUSSION
Focus of the study
This study has compared procedural complication rates according to antithrombotic drug regimens for patients undergoing VT and PVC ablations. It is the first study to provide detailed data on the use of con- We chose to analyze VT and PVC ablation procedure data together due to the frequent use of arterial, and to a lesser extent, trans-septal, access in both settings. For example, femoral arterial access was used in almost 50% of PVC ablation cases (data not shown).
Use of anticoagulants and antiplatelet agents
The majority of patients in Group A received anticoagulant monotherapy, and in Group B received antiplatelet monotherapy. Following the Procedure-related mortality was very low, and almost all patients survived to hospital discharge.
TA B L E 4 Univariable and multivariable analyses of possible predictors of complications
Overall complication rates
Previous trials and studies of VT ablation have reported complication rates between 4% and 11%, with the most common being cardiac perforation and tamponade, major bleeding, stroke, stroke/transient ischemic attack, and lower limb vascular problems. [11] [12] [13] [14] [15] [16] The complication rates for each group in our study were similar to these. Other than the study by Peichl et al., who utilized LMW heparin bridging at the time of procedure, 14 the other studies did not report their approach to antithrombotic therapy.
It is worth noting that although the procedural complication rates for Groups A, B, and C were 8.5%, 6.5%, and 5.6%, respectively, two of the six patients in Group C had more than one complication, such that the complication rate per patient was slightly higher in this group. Interestingly, the cardiac tamponade rate in Group C was higher than Group A, and the only death in the study occurred in this group. Although overall Groups A and B had a higher proportion of VT ablations and comorbidities than Group C (and Group A had more epicardial procedures), the complications in Group C all occurred in patients undergoing VT ablations (and two complications occurred in a 93-year-old patient), such that within Group C, they could be considered to be some of the higher risk procedures.
Multivariable analysis
Multivariable analysis showed that age was the only near-significant variable (P = 0.054), with OR of 1.04, equivalent to a 24% increase in OR for each 5-year increment. This is both plausible, and in keeping with the findings of Peichl et al. 14 They also found a higher complication rate in patients with structural heart disease compared to idiopathic VT, though they did not specify whether the latter included PVC ablation, that is, for nonsustained VT.
Interestingly, we found no significant differences in the risk of complications between the different groups, with both univariable and multivariable analyses, supporting the notion that therapeutic anticoagulation at the time of procedure is safe within the studied INR range (1.6-4.3). Thus, although Group A's complication rate was 8.5% compared to 5.6% in Group C, patients in Group A were older, had more comorbidities, and a lower average LVEF than Group C. In addition, Group A had more VT ablations, and greater use of femoral arterial and epicardial access.
Study limitations
This was a retrospective observational study from a single center with associated selection biases. Despite a reasonably-sized cohort, there
were limited data on the use of dual or triple antithrombotic therapy.
Finally, there was relative heterogeneity between groups limiting the generalizability of the findings.
CONCLUSION
This is the first study to compare complication rates in patients undergoing VT and PVC ablation, according to whether they received anticoagulation, antiplatelet agents, or neither. Our cohort included 201 patients undergoing these procedures in a contemporary setting. Complication rates were similar to those previously published, and small differences in these rates between groups were not significant. Interestingly, there were no trends to bleeding-related complications in the anticoagulation group. These results, therefore, support a strategy of continuing anticoagulation uninterrupted for VT and PVC ablation, with the caveat that prudence be practiced for patients receiving two or three antithrombotic agents, and for those with INRs > 3.5.
